MedTrace Logo

Long-Term Safety of Febuxostat in Subjects With Gout.

NCT00174941 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2011-01-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.

Conditions

Interventions

DRUG

Febuxostat

Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.

DRUG

Febuxostat

Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.

DRUG

Febuxostat

Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2006-12-31
Completion
2006-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174941 on ClinicalTrials.gov